We are live on ! Find out more
NMVA

New Mountain Vantage Advisers Portfolio holdings

AUM $4.33B
1-Year Est. Return 35.3%
This Fund
S&P 500
This Quarter Est. Return
-3.92%
1 Year Est. Return
-35.3%
3 Year Est. Return
+2.05%
5 Year Est. Return
+37.91%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
-$292M
Cap. Flow
-$214M
Cap. Flow %
-11.51%
Top 10 Hldgs %
48.02%
Holding
44
New
3
Increased
10
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$26.9M
2
MCK icon
McKesson
MCK
+$23.6M
3
PFE icon
Pfizer
PFE
+$20M
4
CFG icon
Citizens Financial Group
CFG
+$15.5M
5
CDW icon
CDW
CDW
+$12.7M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$35.8M
2
TMO icon
Thermo Fisher Scientific
TMO
+$24.6M
3
EXP icon
Eagle Materials
EXP
+$22.8M
4
HUM icon
Humana
HUM
+$22.1M
5
UNT
UNIT Corporation
UNT
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.52%
2 Communication Services 22.36%
3 Financials 14.11%
4 Industrials 7.89%
5 Energy 3.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$45B
$31.5M 1.69%
171,973
-127,408
-43% -$22.1M
LILA icon
27
Liberty Latin America Class A
LILA
$1.69B
$29.4M 1.58%
1,310,204
+256,035
+24% +$5.71M
RHP icon
28
Ryman Hospitality Properties
RHP
$8.31B
$26.2M 1.41%
508,906
-209,693
-29% -$10.1M
EXP icon
29
Eagle Materials
EXP
$6.59B
$23M 1.24%
328,192
-392,331
-54% -$22.8M
PFE icon
30
Pfizer
PFE
$143B
$19.7M 1.06%
+700,957
New +$20M
DAL icon
31
Delta Air Lines
DAL
$60.2B
$19.6M 1.06%
402,684
-453,954
-53% -$21.2M
BLPH
32
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$12M 0.64%
323,992
– –
APO icon
33
Apollo Global Management
APO
$74.6B
$11M 0.59%
+643,409
New +$9.65M
HAIN icon
34
Hain Celestial
HAIN
$45.5M
$10.3M 0.56%
+252,367
New +$9.48M
ESRX
35
DELISTED
Express Scripts Holding Company
ESRX
$8.41M 0.45%
122,487
-212,398
-63% -$15.3M
GPI icon
36
Group 1 Automotive
GPI
$3.48B
– –
-215,746
Closed -$16.3M
MCK icon
37
CALL
McKesson
MCK
$96.8B
– –
-80,900
Closed -$16M
RIG icon
38
PUT
Transocean
RIG
$5.7B
– –
-219,400
Closed -$2.72M
TK icon
39
Teekay
TK
$1.03B
– –
-987,982
Closed -$9.75M
TMO icon
40
Thermo Fisher Scientific
TMO
$213B
– –
-173,228
Closed -$24.6M
UNT
41
DELISTED
UNIT Corporation
UNT
– –
-1,797,573
Closed -$21.9M
KS
42
DELISTED
KapStone Paper and Pack Corp.
KS
– –
-928,142
Closed -$21M
APLP
43
DELISTED
Archrock Partners, L.P. Common Units representing Limited Partner Interests
APLP
– –
-874,294
Closed -$10.8M
AVOL
44
DELISTED
AVOLON HLDGS LTD SHS (CYM)
AVOL
– –
-378,233
Closed -$11.7M
1
2

Similar funds

NA
NextCapital Advisers Chicago, Illinois $5.15B AUM 14.37% 1-Year Est. Return
SPF
Steven Patrick Farmer $6.42B AUM
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return
AP
Advisor Partners Walnut Creek, California $1.42B AUM 3.97% 1-Year Est. Return
AWM
Altium Wealth Management Purchase, New York $1.39B AUM 12.44% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BDWM
Brewin Dolphin Wealth Management Conskleagh, Dublin, Ireland $917M AUM 12.3% 1-Year Est. Return
DHFB
Dixon Hubard Feinour & Brown Roanoke, Virginia $842M AUM 2.74% 1-Year Est. Return

New Mountain Vantage Advisers's Q1 2016 Portfolio in Review

As of Q1 2016, New Mountain Vantage Advisers held 44 positions worth $1.86B, down 14% from $2.15B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

New Mountain Vantage Advisers withdrew a net $214M in Q1 2016, closing 9 positions and reducing 20 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 28% a quarter earlier, followed by Communication Services and Financials.

Against the trend, New Mountain Vantage Advisers opened a new position in Pfizer worth $19.7M.

  • New Mountain Vantage Advisers's largest Q1 2016 buy was Pfizer: 700,957 shares worth $19.7M.
  • New Mountain Vantage Advisers added most to Shire pic in Q1 2016, an estimated $26.9M increase.
  • New Mountain Vantage Advisers's biggest Q1 2016 reduction was Allergan plc, cutting an estimated $35.8M.
  • New Mountain Vantage Advisers fully exited Thermo Fisher Scientific in Q1 2016, selling an estimated $24.6M.
  • New Mountain Vantage Advisers's ten largest holdings make up 48% of its $1.86B portfolio in Q1 2016.
  • New Mountain Vantage Advisers opened 3 new positions and closed 9 in Q1 2016.
  • New Mountain Vantage Advisers's portfolio value fell 14% quarter-over-quarter to $1.86B.

Based on New Mountain Vantage Advisers's 13F filing for Q1 2016, filed 16 May 2016.